Danish pharmaceutical invests €2.1 billion in France
On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site to expand the capacity and manufacturing of a blockbuster anti-obesity drug.
Category
🗞
NewsTranscript
00:00 The European Union`s most valuable company is expanding in France. Danish pharmaceutical
00:05 giant Novo Nordisk is investing almost three billion euros in Chartres, a city southwest
00:10 of Paris. The company is known for manufacturing anti-diabetes drugs and will be working on
00:16 Migovi, a popular anti-obesity drug.
00:19 It`s a new drug for the pharmaceutical industry in France. And it`s one of the biggest amounts
00:24 of industrial investment for our country this year. This investment will allow to ensure
00:31 the resilience of production chains in an essential sector, which is health, with the
00:36 doubling of production capacities by 2028.
00:40 President Macron was pushing to bring the pharmaceutical industry back to France after
00:44 several recent drug shortages for antibiotics and pain medicine. Financial experts predict
00:50 that Novo Nordisk will be one of the biggest manufacturers of anti-obesity medication in
00:55 the world by 2030.
00:56 (whooshing)